Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cinacalcet. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR known ✓ | P41180 | 5/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | MC3R | P41968 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinacalcet SCHEMBL29360301 | 1.00 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL1901469 | 1.00 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL29373418 | 1.00 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL3227084 | 1.00 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL30371982 | 1.00 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL1179140 | 0.99 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL195640 | 0.99 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL29364854 | 0.99 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL30482673 | 0.99 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL29363135 | 0.99 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7372 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144585-A1 | TIGHTLY TARGETED MINIMALLY INVASIVE (TTMIT) HYPERFUNCTIONING TISSUE ABLATING INSTRUMENT SYSTEM | Schwartz, Alan N. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-28 | — | — | US | claimed |
| WO-2026106908-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | NEUHYLL THERAPEUTICS INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260102414-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | SANIFIT THERAPEUTICS S A (ES) | 2026-04-16 | — | — | US | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| CN-121586573-A | Lipopolymers for intra-articular administration | 伯尔尼大学 | 2026-02-27 | — | — | CN | claimed |
| US-20060166901-A1 | Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids | YU RUEY J | 2006-07-27 | — | — | US | claimed |
| WO-2006074114-A2 | COMPOSITIONS COMPRISING O-ACETYLSALICYL DERIVATIVES OF AMINOCARBOHYDRATES AND AMINO ACIDS | YU RUEY J (US) | 2006-07-13 | — | — | WO | claimed |
| EP-1663182-A1 | RAPID DISSOLUTION FORMULATION OF A CALCIUM RECEPTOR-ACTIVE COMPOUND | Amgen Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| CN-1758916-A | Method of treating and preventing hyperparathyroidism with vitamin D2 or D4 compounds | BONE CARE INT INC (US) | 2006-04-12 | — | — | CN | claimed |
| WO-2006031719-A2 | 1,4-BIS-N-OXIDE-5,8-DIHYDROXYANTHRACENEDIONE COMPOUNDS AND THE USE THEREOF | NOVACEA, INC. (US) | 2006-03-23 | — | — | WO | claimed |
| US-20050288377-A1 | Use of calcimimetic as an adynamic bone disease related treatment | SCANTIBODIES LABORATORY, INC. | 2005-12-29 | — | — | US | claimed |
| US-20050196418-A1 | Bioavailability and improved delivery of alkaline pharmaceutical drugs | YU RUEY J (US) | 2005-09-08 | — | — | US | claimed |
| US-20050147669-A1 | A mixture of compound, e.g., cinacalcet hydrochloride and excipient in dosage form having a controlled dissolution profile , which comprises 50-125% of a target amount of theactive compound is released in 0.05 hydrochloric acid in 30 minutes; calcimimetics and calcilytics; hyperparathyroidism | AMGEN INC. | 2005-07-07 | — | — | US | claimed |
| WO-2005034928-A1 | RAPID DISSOLUTION FORMULATION OF A CALCIUM RECEPTOR-ACTIVE COMPOUND | AMGEN INC. (US) | 2005-04-21 | — | — | WO | claimed |
| US-6211244-B1 | AROMATIC AMINES FOR COMPLEXING CALCIUM | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | claimed |